Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial-Reference-Cited by-同舟云学术

Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial

Published:2023-12-14 Issue: Volume: Page:
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Postel-Vinay Sophie^ORCID,Coves Juan,Texier Matthieu,Aldea Mihaela^ORCID,Gazzah Anas,Dómine Manuel,Planchard David,De Las Peñas Ramon,Sala Gonzalez Ma Angeles,Viteri Santiago,Perez Javier,Ortega Ana Laura^ORCID,Moran Teresa,Camps Carlos,Lopez-Martin Ana,Provencio Mariano,Soria Jean-Charles,Besse Benjamin,Massuti Bartomeu,Rosell Rafael^ORCID

Funder

AstraZeneca funded the trial and provided the drug Gustave Roussy sponsored this academic trial

AstraZeneca, academic trial

AZ, academic trial

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://www.nature.com/articles/s41416-023-02514-5.pdf

Reference40 articles.

1. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl J Med. 2002;346:92–8.

2. Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012;13:247–55.

3. Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009;374:1432–40.

4. Blais N, Kassouf E. Maintenance therapies for non-small cell lung cancer. Front Oncol. 2014;4:213.

5. Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355:1152–8.